Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
200. lappuse
... concentration or urinary excretion rate during the absorption and elimination phases of a single dose administered at steady - state is encour- aged to permit estimation of the total area under concentration - time curves or cumulative ...
... concentration or urinary excretion rate during the absorption and elimination phases of a single dose administered at steady - state is encour- aged to permit estimation of the total area under concentration - time curves or cumulative ...
258. lappuse
... concentration or within the concentration range established for each ingredient . ( a ) Ephedrine sulfate 0.1 to 1.25 per- cent . ( b ) Epinephrine 0.005 to 0.01 percent . ( c ) Epinephrine hydrochloride 0.005 to 0.01 percent . ( d ) ...
... concentration or within the concentration range established for each ingredient . ( a ) Ephedrine sulfate 0.1 to 1.25 per- cent . ( b ) Epinephrine 0.005 to 0.01 percent . ( c ) Epinephrine hydrochloride 0.005 to 0.01 percent . ( d ) ...
271. lappuse
... concentration specified in the monograph . ( m ) Treatment rinse powder . A fluoride treatment rinse prepared by adding the powder ( a concentrated solid dosage form ) to water before using to result in the appropriate fluoride ...
... concentration specified in the monograph . ( m ) Treatment rinse powder . A fluoride treatment rinse prepared by adding the powder ( a concentrated solid dosage form ) to water before using to result in the appropriate fluoride ...
284. lappuse
... concentration of the coal tar source used and the concentration of the coal tar present in the final product . ( 2 ) Pyrithione zinc , 0.3 to 2 percent when formulated to be applied and then washed off after brief exposure . ( 3 ) ...
... concentration of the coal tar source used and the concentration of the coal tar present in the final product . ( 2 ) Pyrithione zinc , 0.3 to 2 percent when formulated to be applied and then washed off after brief exposure . ( 3 ) ...
366. lappuse
... concentration solu- tion and the other three cylinders with the concentration of the response line under test . Thus , there will be 45 ref- erence concentration zones of inhibi- tion and nine zones of inhibition for each of the other ...
... concentration solu- tion and the other three cylinders with the concentration of the response line under test . Thus , there will be 45 ref- erence concentration zones of inhibi- tion and nine zones of inhibition for each of the other ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning